Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

martin ekwealor pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), calcium pantothenate (unii: 568et80c3d) (pantothenic acid - unii:19f5hk2737), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), biotin (unii: 6so6u10 - ascorbic acid 100 mg - in the wasting syndrome in chronic renal failure; uremia; impaired metabolic functions of the kidney and to maintain levels when dietary intake of vitamins is inadequate or excretion or loss in excessive. also, highly effective as a stress vitamin.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

deseret biologicals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 6 [hp_x] in 1 ml - for temporary relief of symptoms of vitamin c deficiency such as lack of energy, weakness, swollen and tender joints. for temporary relief of symptoms of vitamin c deficiency such as lack of energy, weakness, swollen and tender joints.

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - vitamin c = ascorbic acid - parenteral liquid/solution/suspension - vitamin c = ascorbic acid vitamin-c active 500.0 mg/ml - nutrition & metabolism - dog | guinea pig | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | guinea pig - adult | hi - vitamin | biotin deficiencies | detoxifying agent | erythropoietic activity | stamina | vitamin a | vitamin b | vitamin c | vitamin d | vitamin deficiencies | vitamin e | vitamin k

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalkeith laboratories ltd - ascorbic acid - oral tablet - 50mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalkeith laboratories ltd - ascorbic acid - oral tablet - 100mg

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

hospira, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), retinol (unii: g2sh0xkk91) (retinol - unii:g2sh0xkk91), ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), de - ascorbic acid 80 mg in 5 ml - m.v.i. pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. m.v.i. pediatric is contraindicated in patients who have: - a history of known hypersensitivity to any of the vitamins or excipients in m.v.i. pediatric [see warnings and precautions (5.2), adverse reactions (6)] - an existing hypervitaminosis the safety and effectiveness of m.v.i. pediatric for the prevention of vitamin deficiency have been established in pediatric patients up to 11 years of age receiving parenteral nutrition. the safety and effectiveness of m.v.i. pediatric have not been established in pediatric patients older than 11 years of age. m.v.i. pediatric contains aluminum that may be toxic for premature neonates. aluminum levels should be monitored periodically during administration of m.v.i. pediatric to p

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sandoz canada inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine - unii:x66nso3n35), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (riboflavin - unii:tlm2976ofr), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), d - ascorbic acid 200 mg in 10 ml - infuvite adult is indicated as a daily multivitamin maintenance supplement for adults and children aged 11 and older receiving parenteral nutrition. infuvite adult is also indicated in other situations where administration by the intravenous route is required. such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body’s metabolic demands and consequent tissue depletion of nutrients. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite adult (administered in intravenous fluids under proper dilution) contributes intake of necessary vitamins toward maintaining the body’s normal resistance and repair processes. patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days, as indicated by the clinical st

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

mcguff pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 500 mg in 1 ml - ascor is vitamin c indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. limitations of use ascor is not indicated for treatment of vitamin c deficiency that is not associated with signs and symptoms of scurvy. none. use in specific populations 8.1 pregnancy 8.2 lactation 8.4 pediatric use 8.5 geriatric use 8.6 renal impairment 8.1 pregnancy risk summary there are no available data on use of ascor in pregnant women to inform a drug-associated risk of adverse developmental outcomes; however, use of ascorbic acid (vitamin c) has been used during pregnancy for several decades and no adverse developmental outcomes are reported in the published literature [see data]. there are dose adjustments for ascorbic acid (vitamin c) use during pregnancy [ see clinical considerations ]. animal reproduction studies have not been conducted with ascor. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations dose adjustments during pregnancy and post-partum period follow the u.s. recommended dietary allowances (rda) for pregnant women when considering use of ascor for treatment of scurvy [ see dosage and administration (2.3 )]. data human data there are no available data on use of ascor or another ascorbic acid injection in pregnant women. however, a published meta–analysis of randomized studies evaluating a large number of pregnant women who took oral ascorbic acid (vitamin c) (through diet and supplementation) at doses ranging from 500 to1000 mg/day (2.5 to 5 times the recommended daily intravenous dose, respectively) [ see dosage and administration (2.3) ] between the 9th and 16th weeks of pregnancy showed no increased risk of adverse pregnancy outcomes such as miscarriage, preterm premature rupture of membranes, preterm delivery or pregnancy induced hypertension when compared to placebo. these data cannot definitely establish or exclude the absence of a risk with ascorbic acid (vitamin c) during pregnancy. 8.2 lactation risk summary there are no data on the presence of ascorbic acid (vitamin c) in human milk following intravenous dosing in lactating women. ascorbic acid (vitamin c) is present in human milk after maternal oral intake. maternal oral intake of ascorbic acid (vitamin c) exceeding the u.s. recommended dietary allowances (rda) for lactation does not influence the ascorbic acid (vitamin c) content in breast milk or the estimated daily amount received by breastfed infants. there are no data on the effect of ascorbic acid (vitamin c) on milk production or the breastfed infant. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ascor and any potential adverse effects on the breastfed child from ascor or from the underlying maternal condition. follow the u.s. recommended dietary allowances (rda) for lactating women when considering use of ascor for treatment of scurvy [see dosage and administration (2.3) ]. 8.4 pediatric use ascor is indicated for the short term (up to 1 week) treatment of scurvy in pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. the safety profile of ascorbic acid in pediatric patients is similar to adults; however, pediatric patients less than 2 years of age may be at higher risk of oxalate nephropathy following ascorbic acid administration due to age-related decreased glomerular filtration [ see warnings and precautions (5.1 )]. ascor is not indicated for use in pediatric patients less than 5 months of age. 8.5 geriatric use glomerular filtration rate is known to decrease with age and as such may increase risk for oxalate nephropathy following ascorbic acid administration in elderly population [ see warnings and precautions (5.1 ) ]. 8.6 renal impairment ascor should be used with caution in scorbutic patients with a history of or risk of developing renal oxalate stones or evidence of renal impairment or other issues (e.g., patients on dialysis, patients with diabetic nephropathy, and renal transplant recipients). these patients may be at increased risk of developing acute or chronic oxalate nephropathy following high dose ascorbic acid administration [ see warning and precaution (5.1 ].

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

method pharmaceuticals, llc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with vitamins a, c and d. multi-vitamin drops with fluoride 0.25 mg also provides fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. the american academy of pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25 mg of supplemental fluoride daily which is provided in a dose of 1 ml of multi-vitamin drops with fluoride 0.25 mg (see dosage and administration ). multi-vitamin drops with fluoride 0.25 mg supply significant amounts of vitamins a, c and d to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

method pharmaceuticals, llc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with vitamins a, c and d. multi-vitamin drops with fluoride and iron 0.25 mg also provides fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. the american academy of pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25 mg of supplemental fluoride daily which is provided in a dose of 1 ml of multi-vitamin drops with fluoride 0.25 mg (see dosage and administration ). multi-vitamin drops with fluoride and iron 0.25 mg supply significant amounts of vitamins a, c and d to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride.